# Nieuwe antihyperglycemische middelen en CV-uitkomsten bij diabetes: meta-analyse

*geplaatst 2024-06-01 · Preventie · ESC heart failure · doi 10.1002/ehf2.14726 · https://hartvaat.nl/2024/06/01/nieuwe-antihyperglycemische-middelen-en-cv-uitkomsten-bij-diabetes-meta-analyse/*

Meta-analyse vergeleek de cardiovasculaire uitkomsten van nieuwe antihyperglycemische middelen bij type 2 diabetes. SGLT2-remmers en GLP-1-agonisten bieden complementaire CV-bescherming, DPP-4-remmers zijn CV-neutraal.

## English: Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a meta-analysis.

This meta-analysis compared cardiovascular outcomes of new antihyperglycemic agents in type 2 diabetes, showing that SGLT2 inhibitors and GLP-1 receptor agonists both reduce cardiovascular events while DPP-4 inhibitors are cardiovascularly neutral.

## Abstract (original, from the publication)

AIMS: The study aims to provide comprehensive evidence for the selection of agents in type 2 diabetes mellitus (T2DM) patients with cardiovascular risk and summarize the lasted evidence for the cardiovascular effects of sodium glucose cotransporter-2 inhibitor (SGLT2i) in patients with heart failure (HF). METHODS AND RESULTS: Several online databases were searched. All studies that explored the cardiovascular effects of SGLT2i or glucagon-like peptide 1 receptor agonist (GLP1-RA) were screened and reviewed. A total of 38 studies were included. Compared with GLP1-RA, the use of SGLT2i significantly reduced the risk of cardiovascular death [risk ratio (RR) = 0.59; 95% confidence interval (CI), 0.44-0.58], hospitalization of heart failure (HHF) (RR = 0.77; 95% CI, 0.74-0.80), death from any cause (RR = 0.64; 95% CI, 0.60-0.68), and myocardial infarction (MI) (RR = 0.81; 95% CI, 0.76-0.87). However, SGLT2i significantly increased the risk of stroke (RR = 1.10; 95% CI, 1.04-1.17). Compared with the control group, SGLT2i treatment reduced the risk of cardiovascular death by 14% (RR = 0.86; 95% CI, 0.79-0.94), HHF by 25%, and death from any cause by 9% in patients with HF, regardless of diabetes status. CONCLUSIONS: SGLT2i is associated with a lower risk of cardiovascular death, HHF, death from any cause, and MI in patients with T2DM compared with GLP1-RA. In addition, SGLT2i brought more benefits with respect to the effects of cardiovascular death, HHF, and death from any cause in patients with HF, regardless of diabetes status.

Auteurs: Zijing Zhou, Min Zheng, Zhihong Zuo, Ting Wu

---
Bron: ESC heart failure, https://doi.org/10.1002/ehf2.14726. Bijgewerkt 2026-07-03T13:30:00Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.